Renaissance Investment Group Has Increased Celgene Com (CELG) Holding By $846,872; PROTEON THERAPEUTICS (PRTO) Has 1.57 Sentiment

Celgene Corporation (NASDAQ:CELG) Logo

PROTEON THERAPEUTICS INC (PRTO) investors sentiment increased to 1.57 in 2017 Q4. It’s up 0.43, from 1.14 in 2017Q3. The ratio is more positive, as 11 hedge funds started new and increased holdings, while 7 trimmed and sold holdings in PROTEON THERAPEUTICS INC. The hedge funds in our database now have: 7.22 million shares, up from 7.15 million shares in 2017Q3. Also, the number of hedge funds holding PROTEON THERAPEUTICS INC in top ten holdings was flat from 3 to 3 for the same number . Sold All: 2 Reduced: 5 Increased: 5 New Position: 6.

Renaissance Investment Group Llc increased Celgene Corp Com (CELG) stake by 20.97% reported in 2017Q4 SEC filing. Renaissance Investment Group Llc acquired 8,143 shares as Celgene Corp Com (CELG)’s stock declined 19.30%. The Renaissance Investment Group Llc holds 46,973 shares with $4.90 million value, up from 38,830 last quarter. Celgene Corp Com now has $67.41B valuation. The stock decreased 1.53% or $1.39 during the last trading session, reaching $89.62. About 3.60M shares traded. Celgene Corporation (NASDAQ:CELG) has declined 31.28% since April 20, 2017 and is downtrending. It has underperformed by 42.83% the S&P500.

Abingworth Llp holds 2.7% of its portfolio in Proteon Therapeutics, Inc. for 2.02 million shares. Deer Vii & Co. Ltd. owns 315,101 shares or 2.42% of their US portfolio. Moreover, Mpm Asset Management Llc has 0.75% invested in the company for 983,381 shares. The Massachusetts-based Ra Capital Management Llc has invested 0.21% in the stock. Perceptive Advisors Llc, a New York-based fund reported 334,116 shares.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The company has market cap of $43.30 million. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. It currently has negative earnings.

The stock increased 4.26% or $0.1 during the last trading session, reaching $2.45. About 39,776 shares traded or 2.80% up from the average. Proteon Therapeutics, Inc. (PRTO) has risen 59.38% since April 20, 2017 and is uptrending. It has outperformed by 47.83% the S&P500.

Analysts await Proteon Therapeutics, Inc. (NASDAQ:PRTO) to report earnings on May, 9. They expect $-0.35 EPS, up 10.26% or $0.04 from last year’s $-0.39 per share. After $-0.31 actual EPS reported by Proteon Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 12.90% negative EPS growth.

Since January 1, 0001, it had 1 buying transaction, and 0 sales for $22,560 activity.

Ratings analysis reveals 50% of Proteon Therapeutics’s analysts are positive. Out of 6 Wall Street analysts rating Proteon Therapeutics, 3 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $3.0 while the high is $19.0. The stock’s average target of $10.75 is 338.78% above today’s ($2.45) share price. PRTO was included in 6 notes of analysts from September 22, 2016. The stock of Proteon Therapeutics, Inc. (NASDAQ:PRTO) has “Neutral” rating given on Tuesday, December 13 by Robert W. Baird. The firm has “Buy” rating by H.C. Wainwright given on Thursday, September 22. The stock of Proteon Therapeutics, Inc. (NASDAQ:PRTO) earned “Hold” rating by Stifel Nicolaus on Wednesday, December 14. On Wednesday, December 14 the stock rating was downgraded by JMP Securities to “Mkt Perform”. The rating was upgraded by Raymond James on Wednesday, October 26 to “Strong Buy”. The firm has “Buy” rating given on Thursday, November 10 by Maxim Group.

Among 34 analysts covering Celgene Corporation (NASDAQ:CELG), 19 have Buy rating, 1 Sell and 14 Hold. Therefore 56% are positive. Celgene Corporation has $190 highest and $83 lowest target. $129.76’s average target is 44.79% above currents $89.62 stock price. Celgene Corporation had 142 analyst reports since July 21, 2015 according to SRatingsIntel. On Monday, February 5 the stock rating was maintained by Mizuho with “Buy”. The stock has “Overweight” rating by JP Morgan on Wednesday, March 21. The firm earned “Buy” rating on Wednesday, June 7 by Oppenheimer. The stock of Celgene Corporation (NASDAQ:CELG) has “Neutral” rating given on Friday, June 30 by BTIG Research. The firm has “Buy” rating given on Thursday, December 21 by Guggenheim. The company was downgraded on Friday, January 5 by Bank of America. The stock of Celgene Corporation (NASDAQ:CELG) has “Outperform” rating given on Monday, October 30 by Oppenheimer. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Wednesday, December 13 by Leerink Swann. Standpoint Research initiated the stock with “Buy” rating in Thursday, January 14 report. As per Friday, November 6, the company rating was maintained by UBS.

Since February 8, 2018, it had 1 buy, and 3 selling transactions for $3.58 million activity. LOUGHLIN JAMES J also sold $851,093 worth of Celgene Corporation (NASDAQ:CELG) shares. Alles Mark J also bought $299,594 worth of Celgene Corporation (NASDAQ:CELG) on Thursday, February 8. $1.77M worth of Celgene Corporation (NASDAQ:CELG) shares were sold by KAPLAN GILLA. $1.26 million worth of Celgene Corporation (NASDAQ:CELG) was sold by MARIO ERNEST on Friday, February 23.

Investors sentiment decreased to 0.83 in Q4 2017. Its down 0.34, from 1.17 in 2017Q3. It fall, as 156 investors sold CELG shares while 478 reduced holdings. 118 funds opened positions while 411 raised stakes. 561.38 million shares or 7.06% less from 603.99 million shares in 2017Q3 were reported. Great Lakes Advsrs Ltd Com reported 3,642 shares. Fulton Bancorp Na has 26,128 shares. The Quebec – Canada-based Sector Pension Inv Board has invested 0.06% in Celgene Corporation (NASDAQ:CELG). Buffington Mohr Mcneal owns 0.77% invested in Celgene Corporation (NASDAQ:CELG) for 19,205 shares. First Foundation Advsrs holds 0.14% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 25,127 shares. Pictet Asset Limited has 2.88M shares for 0.77% of their portfolio. Arrowmark Colorado Holdg Ltd Liability Com stated it has 0.19% in Celgene Corporation (NASDAQ:CELG). Opus Point Partners Mgmt Lc accumulated 14,540 shares or 1.31% of the stock. Tompkins Fincl, New York-based fund reported 17,338 shares. Blue Edge Ltd Limited Liability Company holds 0.56% or 13,462 shares. 307,940 are owned by Palo Alto Invsts Ltd Com. Michigan-based World Asset Management Incorporated has invested 0.25% in Celgene Corporation (NASDAQ:CELG). Duff Phelps reported 0.01% in Celgene Corporation (NASDAQ:CELG). Hightower Advsr Limited holds 0.24% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 275,752 shares. Invest House Ltd Company holds 0.92% or 72,411 shares.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart